NO20050018L - Lasofoxifentabletter og belegg - Google Patents
Lasofoxifentabletter og beleggInfo
- Publication number
- NO20050018L NO20050018L NO20050018A NO20050018A NO20050018L NO 20050018 L NO20050018 L NO 20050018L NO 20050018 A NO20050018 A NO 20050018A NO 20050018 A NO20050018 A NO 20050018A NO 20050018 L NO20050018 L NO 20050018L
- Authority
- NO
- Norway
- Prior art keywords
- lasofoxifene
- tablets
- coatings
- active ingredient
- triacetin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Det er beskrevet farmasøytiske preparater hvor lasofoxifen benyttes som en aktiv ingrediens, som har ensartet legemiddelfordeling og styrke og som inneholder et silisiumdioksyd for å redusere tap av den aktive ingrediens under fremstillingsprosessen, og metoder for fremstilling av slike preparater. Triacetin som plastiseringsmiddel i overtrekk, ble vist å gi god stabilitet for lasofoxifen.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39509002P | 2002-07-10 | 2002-07-10 | |
PCT/IB2003/003074 WO2004006895A1 (en) | 2002-07-10 | 2003-06-30 | Lasofoxifene tablet and its coating |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20050018L true NO20050018L (no) | 2005-01-12 |
Family
ID=30115812
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20050018A NO20050018L (no) | 2002-07-10 | 2005-01-03 | Lasofoxifentabletter og belegg |
Country Status (36)
Country | Link |
---|---|
US (2) | US20040057992A1 (no) |
EP (1) | EP1534248B1 (no) |
JP (2) | JP4446446B2 (no) |
KR (1) | KR100782693B1 (no) |
CN (1) | CN100344278C (no) |
AP (1) | AP2005003201A0 (no) |
AR (1) | AR040434A1 (no) |
AT (1) | ATE550017T1 (no) |
AU (1) | AU2003247017B2 (no) |
BR (1) | BR0312563A (no) |
CA (1) | CA2489407C (no) |
CY (1) | CY1112892T1 (no) |
DK (1) | DK1534248T3 (no) |
EA (1) | EA007268B1 (no) |
EC (1) | ECSP055528A (no) |
ES (1) | ES2395123T3 (no) |
HK (1) | HK1077747A1 (no) |
HN (1) | HN2003000206A (no) |
HR (1) | HRP20041196A2 (no) |
IL (2) | IL165746A0 (no) |
IS (1) | IS7594A (no) |
MA (1) | MA27318A1 (no) |
MX (1) | MXPA05000394A (no) |
NO (1) | NO20050018L (no) |
NZ (1) | NZ537278A (no) |
OA (1) | OA12883A (no) |
PA (1) | PA8576201A1 (no) |
PE (1) | PE20040104A1 (no) |
PL (1) | PL374913A1 (no) |
PT (1) | PT1534248E (no) |
SI (1) | SI1534248T1 (no) |
TN (1) | TNSN05006A1 (no) |
TW (1) | TW200406222A (no) |
UY (1) | UY27886A1 (no) |
WO (1) | WO2004006895A1 (no) |
ZA (1) | ZA200410196B (no) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PA8576201A1 (es) * | 2002-07-10 | 2004-05-26 | Pfizer Prod Inc | Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco |
US20040253305A1 (en) * | 2003-06-12 | 2004-12-16 | Luner Paul E. | Pharmaceutical compositions of atorvastatin |
US20050271717A1 (en) * | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
WO2006105806A1 (en) * | 2005-04-07 | 2006-10-12 | Miso Sabovic | Delaying the ageing process and disorders caused by ageing |
EP1878426B1 (en) * | 2005-04-26 | 2010-06-16 | Dainippon Sumitomo Pharma Co., Ltd. | Granular preparation containing biguanide compound |
GB0516604D0 (en) * | 2005-08-12 | 2005-09-21 | Sandoz Ag | Rapidly dispersing/disintegrating compositions |
JP5688877B2 (ja) | 2005-11-11 | 2015-03-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌疾患の治療用キナゾリン誘導体 |
SG183059A1 (en) | 2007-02-23 | 2012-08-30 | Gilead Sciences Inc | Modulators of pharmacokinetic properties of therapeutics |
CA2587805C (en) * | 2007-04-25 | 2014-02-18 | The Procter & Gamble Company | Improved vitamin d content uniformity in pharmaceutical dosage forms |
MY164765A (en) * | 2007-10-10 | 2018-01-30 | Avantor Performance Mat Llc | Directly compressible high functionality granular microcrystalline cellulose based excipient, manufacturing process and use thereof |
US20100055180A1 (en) * | 2007-10-10 | 2010-03-04 | Mallinckrodt Baker, Inc. | Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof |
WO2009135067A1 (en) * | 2008-05-01 | 2009-11-05 | Wyeth | Pharmaceutical polish formulations |
KR101659971B1 (ko) * | 2008-05-02 | 2016-09-26 | 길리애드 사이언시즈, 인코포레이티드 | 제약 제제의 가공성 향상을 위한 고체 담체 입자의 용도 |
PT2451445T (pt) * | 2009-07-06 | 2019-07-10 | Boehringer Ingelheim Int | Processo para secagem de bibw2992, dos seus sais e de formulações farmacêuticas sólidas compreendendo este ingrediente ativo |
CA2851862C (en) * | 2011-10-17 | 2020-04-14 | Lexicon Pharmaceutical Inc. | Solid dosage forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate |
EP2851075B1 (en) | 2012-05-14 | 2021-12-01 | Shionogi & Co., Ltd. | Preparation containing 6,7-unsaturated-7-carbamoylmorphinan derivative |
US20160220494A1 (en) * | 2013-09-13 | 2016-08-04 | Bayer Pharma Aktiengesellschaft | Pharmaceutical compositions containing refametinib |
RU2539375C1 (ru) * | 2013-11-07 | 2015-01-20 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Фармацевтическая композиция в форме таблетки и способ ее получения |
US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
CN103830196A (zh) * | 2014-03-14 | 2014-06-04 | *** | 一种酒石酸拉索昔芬分散片及其制备方法 |
TWI535784B (zh) | 2014-08-26 | 2016-06-01 | 財團法人工業技術研究院 | 剪切增稠配方、及包含其之複合材料 |
CN105434444B (zh) * | 2014-09-29 | 2021-02-05 | 上海奥奇医药科技有限公司 | 一种A-失碳-5α雄甾烷化合物的口服制剂 |
US20190183850A1 (en) * | 2016-07-25 | 2019-06-20 | Canopy Growth Corporation | New cannabis tablet formulations and compositions and methods of making the same |
DK3525774T3 (da) | 2016-10-11 | 2022-03-14 | Univ Duke | Lasofoxifen behandling af er+ brystcancer |
CN112261937B (zh) | 2018-04-10 | 2023-11-14 | 杜克大学 | 乳腺癌的拉索昔芬治疗 |
GB202116903D0 (en) | 2021-11-18 | 2022-01-05 | Sermonix Pharmaceuticals Inc | Lasofoxifene treatment of aromatase-resistant er+ cancer |
CN114288258A (zh) * | 2022-02-18 | 2022-04-08 | 山东新时代药业有限公司 | 一种单硝酸异山梨酯片及其制备方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4182A (en) * | 1845-09-09 | Island | ||
US4880636A (en) * | 1988-05-13 | 1989-11-14 | Franz Robert M | Film coated tablet of ranitidine HCl |
US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
UA51676C2 (uk) | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція |
TW442286B (en) * | 1996-02-28 | 2001-06-23 | Pfizer | New therapeutic uses of estrogen agonists |
US6372457B1 (en) | 1997-01-14 | 2002-04-16 | Arkion Life Sciences Llc | Process and materials for production of glucosamine |
KR200161927Y1 (ko) * | 1997-08-26 | 1999-12-01 | 윤종용 | 냉장고 |
YU26700A (sh) | 1999-05-24 | 2002-06-19 | Pfizer Products Inc. | Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin |
US6436977B1 (en) * | 1999-09-29 | 2002-08-20 | Pfizer Inc. | Dosing regimens for lasofoxifene |
US6419956B1 (en) * | 1999-12-30 | 2002-07-16 | Ancile Pharmaceuticals | Odor-masking coating for a pharmaceutical preparation |
EP1145719A3 (en) * | 2000-03-10 | 2001-11-14 | Pfizer Products Inc. | Use a ferrous salt for inhibiting oxidative degradation of pharmaceutical formulations |
AR029538A1 (es) * | 2000-07-06 | 2003-07-02 | Wyeth Corp | Composiciones farmaceuticas de agentes estrogenicos |
NZ528886A (en) * | 2001-05-01 | 2005-04-29 | Pfizer Prod Inc | A dry process for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency |
PA8576201A1 (es) * | 2002-07-10 | 2004-05-26 | Pfizer Prod Inc | Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco |
-
2003
- 2003-06-23 PA PA20038576201A patent/PA8576201A1/es unknown
- 2003-06-30 JP JP2004521001A patent/JP4446446B2/ja not_active Expired - Fee Related
- 2003-06-30 PL PL03374913A patent/PL374913A1/xx not_active Application Discontinuation
- 2003-06-30 AP AP2005003201A patent/AP2005003201A0/xx unknown
- 2003-06-30 EA EA200401583A patent/EA007268B1/ru not_active IP Right Cessation
- 2003-06-30 AT AT03764059T patent/ATE550017T1/de active
- 2003-06-30 OA OA1200500007A patent/OA12883A/en unknown
- 2003-06-30 DK DK03764059.6T patent/DK1534248T3/da active
- 2003-06-30 EP EP03764059A patent/EP1534248B1/en not_active Expired - Lifetime
- 2003-06-30 KR KR1020057000369A patent/KR100782693B1/ko active IP Right Grant
- 2003-06-30 SI SI200332150T patent/SI1534248T1/sl unknown
- 2003-06-30 MX MXPA05000394A patent/MXPA05000394A/es active IP Right Grant
- 2003-06-30 NZ NZ537278A patent/NZ537278A/en unknown
- 2003-06-30 BR BR0312563-7A patent/BR0312563A/pt not_active IP Right Cessation
- 2003-06-30 ES ES03764059T patent/ES2395123T3/es not_active Expired - Lifetime
- 2003-06-30 PT PT03764059T patent/PT1534248E/pt unknown
- 2003-06-30 WO PCT/IB2003/003074 patent/WO2004006895A1/en not_active Application Discontinuation
- 2003-06-30 CA CA002489407A patent/CA2489407C/en not_active Expired - Fee Related
- 2003-06-30 IL IL16574603A patent/IL165746A0/xx unknown
- 2003-06-30 CN CNB038162881A patent/CN100344278C/zh not_active Expired - Fee Related
- 2003-06-30 AU AU2003247017A patent/AU2003247017B2/en not_active Ceased
- 2003-07-01 US US10/612,679 patent/US20040057992A1/en not_active Abandoned
- 2003-07-04 TW TW092118389A patent/TW200406222A/zh unknown
- 2003-07-07 PE PE2003000682A patent/PE20040104A1/es not_active Application Discontinuation
- 2003-07-07 HN HN2003000206A patent/HN2003000206A/es unknown
- 2003-07-08 AR AR20030102454A patent/AR040434A1/es not_active Application Discontinuation
- 2003-07-08 UY UY27886A patent/UY27886A1/es not_active Application Discontinuation
-
2004
- 2004-12-13 IL IL165746A patent/IL165746A/en active IP Right Grant
- 2004-12-13 IS IS7594A patent/IS7594A/is unknown
- 2004-12-17 HR HR20041196A patent/HRP20041196A2/hr not_active Application Discontinuation
- 2004-12-17 ZA ZA200410196A patent/ZA200410196B/en unknown
-
2005
- 2005-01-03 NO NO20050018A patent/NO20050018L/no not_active Application Discontinuation
- 2005-01-10 TN TNP2005000006A patent/TNSN05006A1/fr unknown
- 2005-01-10 MA MA28036A patent/MA27318A1/fr unknown
- 2005-01-10 EC EC2005005528A patent/ECSP055528A/es unknown
- 2005-11-04 HK HK05109850A patent/HK1077747A1/xx not_active IP Right Cessation
-
2006
- 2006-11-09 JP JP2006303440A patent/JP2007031451A/ja active Pending
- 2006-12-22 US US11/615,511 patent/US7553500B2/en not_active Expired - Fee Related
-
2012
- 2012-06-06 CY CY20121100504T patent/CY1112892T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20050018L (no) | Lasofoxifentabletter og belegg | |
TW200745111A (en) | New compounds | |
MX2009006401A (es) | Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer. | |
NO20062884L (no) | AKT-proteinkinaseinhibitorer | |
NO20073959L (no) | Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller | |
TW200621762A (en) | Novel compounds | |
NO20092737L (no) | Substituerte pyrazolo-kinazolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som kinase-inhibitorer | |
WO2001087839A8 (en) | Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity | |
MXPA06000302A (es) | Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden. | |
NO20011721D0 (no) | N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor | |
NO20070570L (no) | Forbindelser. | |
UA90285C2 (ru) | Производные гидантоина, полезные как ингибиторы металлопротеиназ | |
TW200606164A (en) | New compounds | |
DE602004011966D1 (en) | Heterocyclylverbindungen | |
BRPI0413438A (pt) | derivados de pirimidilpirrol ativos como inibidores de cinase | |
NO20020282L (no) | Nytt difenyl-piperidinderivat | |
TW200800984A (en) | New compounds | |
WO2003057150A3 (en) | A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof | |
IL151359A0 (en) | Esmolol formulation | |
WO2001000617A3 (en) | Novel piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the same | |
NO20083441L (no) | Benzoisoindolderivater for behandling av smerte | |
WO2004106307A3 (fr) | Nouveaux derives d’imidazoles, leur preparation et leur utilisation en tant que medicament | |
WO2004056808A8 (en) | Novel piperidine derivatives as modulators of chemokine receptor ccr5 | |
WO2004056809A8 (en) | Novel piperidine derivatives as modulators of chemokine receptor ccr5 | |
WO2005034954A3 (en) | Pharmaceutical compositions of paroxetine containing microcrystalline cellulose, prepared by wet granulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |